| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
New Frontier Health Corporation (NYSE:NFH) (“NFH” or the “Company”), the operator of the premium healthcare services provider United Family Healthcare, today reported that, on January 4, 2022, the Company received a notice from the New York Stock Exchange (the “NYSE”) Regulation stating that it is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria pursuant to Section 802.01E of the NYSE Listed Company Manual (the “Continued Listing Criteria”) as a result of the Company’s failure to timely file its semi-annual financial information for the half year ended June 30, 2021 on a Current Report on Form 6-K (the “1H 2021 6-K”) with the SEC.
The NYSE informed the Company that, under the NYSE’s rules, the Company has six months from December 31, 2021 to file the 1H 2021 6-K with the SEC (the “Automatic Cure Period”). If the Company fails to file the 1H 2021 6-K within the Automatic Cure Period, the NYSE may, in its sole discretion, allow the Company’s securities to trade for up to an additional six months depending on specific circumstances (the “Additional Cure Period”), as outlined in the Continued Listing Criteria. If the NYSE determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence pursuant to Section 804.00 of the NYSE Listed Company Manual. If the NYSE determines that an Additional Cure Period is appropriate and the Company fails to file the 1H 2021 6-K by the end of that period, suspension and delisting procedures will generally commence. Regardless of the procedures described above, the NYSE may commence delisting proceedings at any time during the period that is available to the Company to complete the filing of the 1H 2021 6-K, if circumstances warrant.
The Company has not yet filed the 1H 2021 6-K with the SEC because it has focused its resources on its previously announced going private transaction (the “Privatization”), which is expected to close during the first quarter of 2022. If consummated, the Privatization would result in the Company becoming a privately held company and its ordinary shares and warrants would no longer be listed on the NYSE. If the Company completes the Privatization before the end of the Automatic Cure Period (or Additional Cure Period, if applicable), the Company does not intend to file the 1H 2021 6-K since its securities will no longer be listed on the NYSE.
Posted In: NFH
